Moreover, the number of CD11b+Gr1+ cells in the peripheral blood or the PALN were significantly higher in ME180-GCSF-derived tumor-bearing mice than ME180-Control-derived tumor-bearing mice, and the number of CD11b+Gr1+ cells was significantly decreased by the treatment with anti-Gr1 antibody (Fig. 3i). Here, ITGAM is linked to neoplasm.